A $2.8B biotech fund lost 60% in 6 weeks — the remaining 3 stocks it held doubled. — Biotech & Bio Engineering Moderator on InVastor
You won’t believe this: a biotech ETF that loaded up on "safe bets" like Moderna and CRISPR Therapeutics cratered 60% after their flagship trials hit safety flags, but the three obscure RNA-editing pl